Fc-silenced bispecific antibodies targeting PD-L1 and 4-1BB combine checkpoint blockade and T-cell co-stimulation to promote anti-tumor activity

被引:0
|
作者
Muik, Alexander [1 ]
Altintas, Isil [2 ]
Gieseke, Friederike [1 ]
Salcedo, Theodora [2 ]
Burm, Saskia [2 ]
Diken, Mustafa [1 ]
Grunwitz, Christian [1 ]
Schuurhuis, Danita [2 ]
Kreiter, Sebastian [1 ]
Satijn, David [2 ]
Tureci, Ozlem [1 ]
Breij, Esther [2 ]
Sahin, Ugur [1 ]
Jure-Kunkel, Maria [2 ]
机构
[1] BioNTech SE, Mainz, Germany
[2] Genmab, Utrecht, Netherlands
来源
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P609
引用
收藏
页数:2
相关论文
共 50 条
  • [1] Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
    Sam, Johannes
    Colombetti, Sara
    Fauti, Tanja
    Roller, Andreas
    Biehl, Marlene
    Fahrni, Linda
    Nicolini, Valeria
    Perro, Mario
    Nayak, Tapan
    Bommer, Esther
    Schoenle, Anne
    Karagianni, Maria
    Le Clech, Marine
    Steinhoff, Nathalie
    Klein, Christian
    Umana, Pablo
    Bacac, Marina
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [2] An Fc-inert PD-L1x4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation
    Muik, Alexander
    Altintas, Isil
    Gieseke, Friederike
    Schoedel, Kristina B.
    Burm, Saskia M.
    Toker, Aras
    Salcedo, Theodora W.
    Verzijl, Dennis
    Eisel, David
    Grunwitz, Christian
    Kranz, Lena M.
    Vormehr, Mathias
    Satijn, David P. E.
    Diken, Mustafa
    Kreiter, Sebastian
    Sasser, Kate
    Ahmadi, Tahamtan
    Tuereci, Oezlem
    Breij, Esther C. W.
    Jure-Kunkel, Maria
    Sahin, Ugur
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [3] Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade
    Warmuth, Stefan
    Gunde, Tea
    Snell, Daniel
    Brock, Matthias
    Weinert, Christopher
    Simonin, Alexandre
    Hess, Christian
    Tietz, Julia
    Johansson, Maria
    Spiga, Fabio Mario
    Heiz, Robin
    Fluckiger, Naomi
    Wagen, Sandro
    Zeberer, Julia
    Diem, Dania
    Mahler, Dana
    Wickihalder, Belinda
    Muntwiler, Simone
    Chatterjee, Bithi
    Kuttner, Benjamin
    Bommer, Bettina
    Yaman, Yasemin
    Lichtlen, Peter
    Urech, David
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [4] KEY PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS THAT CORRELATE WITH THE ANTI-TUMOR ACTIVITY OF A BISPECIFIC PD-L1 CONDITIONAL 4-1BB AGONIST
    Kinkead, Heather
    Macedo, Chelsie
    Sanabria, Angelica
    Cyprus, Garrett
    Pandit, Rajay
    Kalabus, James
    Becklund, Bryan
    Sulzmaier, Florian
    Timmer, John
    Deveraux, Quinn
    Eckelman, Brendan
    Heidt, Analeah
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A12 - A12
  • [5] The bispecific antibody KA-3004, targeting PD-L1 and 4-1BB, is designed to enhance anti- tumor activity
    Liang, Jiabei
    Guo, Zhengcheng
    Peng, Hao
    Hao, Feng
    Liu, Tongtong
    Ning, Jinying
    Wu, Guojin
    CANCER RESEARCH, 2024, 84 (06)
  • [6] Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity (vol 10, 575737, 2020)
    Sam, Johannes
    Colombetti, Sara
    Fauti, Tanja
    Roller, Andreas
    Biehl, Marlene
    Fahrni, Linda
    Nicolini, Valeria
    Perro, Mario
    Nayak, Tapan
    Bommer, Esther
    Schoenle, Anne
    Karagianni, Maria
    Le Clech, Marine
    Steinhoff, Nathalie
    Klein, Christian
    Umana, Pablo
    Bacac, Marina
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
    Dahan, Rony
    Sega, Emanuela
    Engelhardt, John
    Selby, Mark
    Korman, Alan J.
    Ravetch, Jeffrey V.
    CANCER CELL, 2015, 28 (03) : 285 - 295
  • [8] Vascular Targeting Viral Therapy Augments Pd-L1 Checkpoint Blockade Anti-Tumor Activity
    Breitbart, Eyal
    Mendel, Itzhak
    Yacov, Niva
    MOLECULAR THERAPY, 2017, 25 (05) : 270 - 271
  • [9] ATG-101, A NOVEL PD-L1/4-1BB BISPECIFIC ANTIBODY, AUGMENTS ANTI-TUMOR IMMUNITY THROUGH IMMUNE CHECKPOINT INHIBITION AND PDL1-DIRECTED 4-1BB ACTIVATION
    Hui Yuwen
    Li, Tengteng
    Ren, Yijing
    Hoenemann, Dirk
    Mei, Jay
    Shan, Bo
    Hou, Bing
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A936 - A937
  • [10] MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
    Ebert, Peter J. R.
    Cheung, Jeanne
    Yang, Yagai
    McNamara, Erin
    Hong, Rebecca
    Moskalenko, Marina
    Gould, Stephen E.
    Maecker, Heather
    Irving, Bryan A.
    Kim, Jeong M.
    Belvin, Marcia
    Mellman, Ira
    IMMUNITY, 2016, 44 (03) : 609 - 621